1997
DOI: 10.1136/bmj.315.7119.1363
|View full text |Cite
|
Sign up to set email alerts
|

Lesson of the week: Oxybutynin and cognitive dysfunction

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
68
1
1

Year Published

1999
1999
2016
2016

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 137 publications
(70 citation statements)
references
References 8 publications
0
68
1
1
Order By: Relevance
“…[15][16][17] In this case, hallucinations stopped seven days after stopping fesoterodine. As the half-life for 5-HMT is approximately eight hours, complete elimination would be expected after 40-56 hours (5-7 half-life).…”
Section: Discussionmentioning
confidence: 70%
“…[15][16][17] In this case, hallucinations stopped seven days after stopping fesoterodine. As the half-life for 5-HMT is approximately eight hours, complete elimination would be expected after 40-56 hours (5-7 half-life).…”
Section: Discussionmentioning
confidence: 70%
“…Of significant concern are the suggested cognitive side-effects, particularly as these children represent a neurologically vulnerable cohort. [8] For children who are not controlled by anticholinergic therapy and clean intermittent catheterisation, other options need to be explored, as discussed below. These patients may have persistent hydronephrosis, new renal scarring, vesico-ureteric reflux, persistent incontinence or UTIs.…”
Section: Pharmacotherapymentioning
confidence: 99%
“…Second generation antihistamines that have very limited effects on cognitive function in healthy subjects were also considered to have no CNS activity. Subjects taking CNS-active medications with mild or infrequent side effects on cognition or fatigue (e.g., SSRIs [21], beta-blockers [20], anticholinergics for bladder dysfunction [13,16]) or drugs with more consistent or more marked negative effects on cognitive function or fatigue (e.g., benzodiazepines, tricyclic antidepressants) were assigned to a second group.…”
Section: Medicationsmentioning
confidence: 99%
“…Many other drugs used by people with MS may negatively affect cognitive function as assessed by controlled trials in healthy control subjects, patient groups, or animals. This list includes tricyclic antidepressants, anticholinergics, first generation antihistamines, baclofen, beta-blockers, amantadine, selective serotonin reuptake inhibitors (SSRIs), and benzodiazepines [6][7][11][12][13][14][15][16][17][18][19][20][21]. On the other hand, methylphenidate and related drugs (modafinil) improve some cognitive functions in healthy subjects [11,[22][23].…”
Section: Introductionmentioning
confidence: 99%